AArkstore enterprise 5th December 2014
Hepatitis B Ther apeutics - Pipeline Assessment and Market Forecasts to Browse Full Report @ http://www.aarkstore.com/pharmaceuticals-healthcare/60345/hepatitis-b-therapeuticspipeline-assessment-and-market-forecasts Published: Mar 2012 | No. Of Pages: 103 Pages PDF: $ 3995 | Site Licence : $ 7990 | Enterprise Wide Licence : $ 11985
2019
Summary The industry analysis specialist, has released its new report, “Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019�. The report is an essential source of information and analysis on the global hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global hepatitis B therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis B therapeutics market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Website : http://www.aarkstore.com/
AArkstore enterprise GlobalData’s analysis shows that the global hepatitis B therapeutics market stood at $2,018.7m in 2006 and grew at a Compound Annual Growth Rate (CAGR) of 8.6% to reach $3,056.0m in 2011. GlobalData forecasts that the global hepatitis B therapeutics market will grow at a slow rate with a CAGR of 4.8% over the forecast period to reach $4,441.3m by 2019. The low growth in the global hepatitis B therapeutics market can be attributed to the high vaccination coverage rates in developed countries, resulting in lower incidence rates of hepatitis B. The hepatitis B therapeutics market is also set to witness the patent expiry of most of the nucleoside analogues between 2013 and 2017. The patent expiry of the immunologic Pegasys (peginterferon alfa-2a) in 2018 will, however, not impact the market significantly. The high growth rate in the historic period may be attributed to the launch of Pegasys, Tyzeka (telbivudine), Viread (tenovofir) and Baraclude (entecavir) between 2005 and 2008, and the high Annual Cost of Therapy (ACoT) for the pegylated interferon therapy.
Scope The report provides information on the key drivers and challenges of the hepatitis B therapeutics market. Its scope includes - Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan hepatitis B therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as HBsAg release blocker, HBV DNA polymerase inhibitor, HBV DNA polymerase inhibitor and immunomodulator, HBV DNA polymerase inhibitor and microtubule assembly inhibitor, HBV therapeutic vaccine, HBV therapeutic vaccine and HBV DNA polymerase inhibitor, Hydroxymethyl glutarate coenzyme A (HMG-CoA) reductase inhibitor, Immunomodulator, Protease inhibitor and others. - Analysis of the current and future competition in the seven key countries hepatitis B therapeutics market. Key market players covered are GlaxoSmithKline, Bristol-Myers Squibb, Daewoong Pharmaceutical Co., Ltd., Chongqing Jiachen Biotechnology Ltd, Chongqing Tongjunge Co., Ltd., LG Life Sciences, Ltd, Bristol-Myers Squibb Company, Phytrix Inc., Medivir AB, AiCuris GmbH & Co. KG, Gilead Sciences, Inc., VectorLogics, Inc., Genexine Co., Ltd., GenPhar, Inc., Cytheris SA, Bolder Biotechnology, Inc, ImQuest Life Sciences, Aduro BioTech, Agenix Limited, Xenetic Biosciences plc, MOLOGEN AG, NanoBio Corporation, Inbiopro Solutions Pvt. Ltd., Gilead Sciences, Merck & Co. Inc. and Novartis AG, - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the hepatitis B therapeutics market.
Website : http://www.aarkstore.com/
AArkstore enterprise - Analysis of key recent licensing and partnership agreements in hepatitis B therapeutics market
Reasons to buy The report will enhance your decision making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global hepatitis B therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global hepatitis B therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What’s the next big thing in the global hepatitis B therapeutics market landscape? – Identify, understand and capitalize.
Website : http://www.aarkstore.com/
AArkstore enterprise Special Discount on Global Data Market Research Reports: Click here an avail Discount offer on Global Data market research reports: http://www.aarkstore.com/discount.php Discount Valid till 31st December 2014 For Research Reports Call us on: +91 9987295242 OR Mail us at contact@aarkstore.com
Tables Of Contents 2 Hepatitis B Therapeutics - Introduction 2.1 Overview 2.2 Epidemiology 2.3 Disease Burden 2.4 Etiology
Website : http://www.aarkstore.com/
AArkstore enterprise 2.5 Symptoms 2.6 Diagnosis 2.7 Pathophysiology 2.8 Treatment and Management Pattern 2.9 GlobalData Pipeline Report Guidance 3 Hepatitis B Therapeutics - Market Characterization 3.1 Hepatitis B Therapeutics Market Size (2006 - 2011) - Global 3.2 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Global 3.3 Hepatitis B Therapeutics Market Size (2006 - 2011) - The US 3.4 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - The US 3.5 Hepatitis B Therapeutics Market Size (2006 - 2011) - France 3.6 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - France 3.7 Hepatitis B Therapeutics Market Size (2006 - 2011) - Germany 3.8 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Germany 3.9 Hepatitis B Therapeutics Market Size (2006 - 2011) - Italy 3.10 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Italy 3.11 Hepatitis B Therapeutics Market Size (2006 - 2011) - Spain 3.12 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Spain 3.13 Hepatitis B Therapeutics Market Size (2006 - 2011) - The UK 3.14 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - The UK 3.15 Hepatitis B Therapeutics Market Size (2006 - 2011) - Japan 3.16 Hepatitis B Therapeutics Market Forecast (2011 - 2019) - Japan 3.17 Drivers and Barriers for the Hepatitis B Therapeutics Market
Website : http://www.aarkstore.com/
AArkstore enterprise 3.17.1 Drivers for the Hepatitis B Therapeutics Market 3.17.2 Barriers for the Hepatitis B Therapeutics Market 3.18 Opportunity and Unmet Need 3.19 Key Takeaway 4 Hepatitis B Therapeutics - Competitive Assessment 4.1 Overview 4.2 Strategic Competitor Assessment 4.3 Product Profile for the Major Marketed Drugs 4.3.1 Intron A (interferon alpha 2b) 4.3.2 Pegasys (peginterferon alfa-2a) 4.3.3 Baraclude (entecavir) 4.3.4 Tyzeka (telbivudine) 4.3.5 Hepsera (adevofir) 4.3.6 Epivir-HBV (lamivudine) 4.3.7 Viread (tenovofir) 4.4 Key Takeaway 5 Hepatitis B Therapeutics - Pipeline Assessment 5.1 Overview 5.2 Strategic Pipeline Assessment 5.3 Hepatitis B Therapeutics - Pipeline Analysis by Clinical Phase of Development 5.3.1 Hepatitis B Therapeutics - Phase III Clinical Pipeline 5.3.2 Hepatitis B Therapeutics - Phase II Clinical Pipeline 5.3.3 Hepatitis B Therapeutics - Phase I Pipeline
Website : http://www.aarkstore.com/
AArkstore enterprise 5.3.4 Hepatitis B Therapeutics - Preclinical Phase Pipeline 5.3.5 Hepatitis B Therapeutics - NA Phase Pipeline 5.4 Hepatitis B Therapeutics - Pipeline by Mechanism of Action 5.5 Technology Trends Analytical Framework 5.6 Key Takeaway 6 Hepatitis B Therapeutics - Clinical Trials Mapping 6.1 Overview 6.2 Clinical Trials by Region/Country (The US, EU5 and Japan) 6.3 Clinical Trials by Phase of Clinical Development 6.4 Clinical Trials by Trial Status 6.5 Prominent Sponsors 6.6 Clinical Trials by Sponsors 6.7 Top Companies Participating in Hepatitis B Therapeutics Clinical Trials 6.8 Key Takeaway 7 Hepatitis B Therapeutics - Strategic Assessment 7.1 Key Events Impacting the Future Market 7.2 Future Market Competition Scenario 8 Hepatitis B Therapeutics - Future Players 8.1 Introduction 8.2 Company Profiles 8.2.1 Bristol-Myers Squibb Company 8.2.2 Gilead Sciences 8.2.3 GlaxoSmithKline Plc
Website : http://www.aarkstore.com/
AArkstore enterprise 8.2.4 F. Hoffmann-La Roche 8.2.5 Merck & Co. Inc. 8.2.6 Novartis AG 8.3 Other Companies 8.4 Key Takeaway 9 Hepatitis B Therapeutics - Licensing & Partnership Deals 10 Hepatitis B Therapeutics - Appendix 10.1 Market Definitions 10.2 Abbreviations 10.3 Research Methodology 10.3.1 Coverage 10.3.2 Secondary Research 10.3.3 Forecasting 10.3.4 Primary Research 10.3.5 Expert Panel Validation 10.4 Contact Us 10.5 Disclaimer 10.6 Bibliography
List Of Tables Table 1: Hepatitis B - Nomenclature of Hepatitis B Table 2: Hepatitis B - Laboratory Nomenclature Table 3: Hepatitis B - Approved Vaccines for Hepatitis B
Website : http://www.aarkstore.com/
AArkstore enterprise Table 4: Hepatitis B - Approved Drugs for Hepatitis B Table 5: Hepatitis B Therapeutics Market, Global, Revenue ($m), 2006 - 2011 Table 6: Hepatitis B Therapeutics Market, Global, Forecast ($m), 2011 - 2019 Table 7: Hepatitis B Therapeutics Market, The US, Revenue ($m), 2006 - 2011 Table 8: Hepatitis B Therapeutics Market, The US, Forecast ($m), 2011 - 2019 Table 9: Hepatitis B Therapeutics Market, France, Revenue ($m), 2006 - 2011 Table 10: Hepatitis B Therapeutics Market, France, Forecast ($m), 2011 - 2019 Table 11: Hepatitis B Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 Table 12: Hepatitis B Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 Table 13: Hepatitis B Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 Table 14: Hepatitis B Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 Table 15: Hepatitis B Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 Table 16: Hepatitis B Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 Table 17: Hepatitis B Therapeutics Market, The UK, Revenue ($m), 2006 - 2011 Table 18: Hepatitis B Therapeutics Market, The UK, Forecast ($m), 2011 - 2019 Table 19: Hepatitis B Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 Table 20: Hepatitis B Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 Table 21: Histological Improvement and Change in Ishak Fibrosis Score at Week 52 (007 GLOBE Study) Table 22: The Results for Measures of Response Included Change in Serum HBV DNA, Change in ALT, HBeAg loss and HBeAg Seroconversion (437 Only) Table 23: Changes in Ishak Fibrosis Score at Week 48 Table 24: Histologic Response at Week 52 Among Adult Patients Receiving Epivir-HBV 100mg Once Daily or Placebo Table 25: HBeAg Seroconversion at Week 52 Among Adult Patients Receiving Epivir-HBV 100mg Once Daily or Placebo Table 26: Clinical Study Results - Viread
Website : http://www.aarkstore.com/
AArkstore enterprise Table 27: Hepatitis B Therapeutics Market, Phase III Pipeline, 2011 Table 28: Hepatitis B Therapeutics Market, Phase II Pipeline, 2011 Table 29: Hepatitis B Therapeutics Market, Phase I Pipeline, 2011 Table 30: Hepatitis B Therapeutics Market, Preclinical Phase Pipeline, 2011 Table 31: Hepatitis B Therapeutics Market, NA Phase Pipeline, 2011 Table 32: Hepatitis B Therapeutics, Global, Clinical Trials, 2011 Table 33: Hepatitis B Therapeutics, Global, Clinical Trials by Phase, 2011 Table 34: Hepatitis B Therapeutics, Global, Clinical Trials by Status of Development, 2011 Table 35: Hepatitis B Therapeutics, Global, Prominent Sponsors, 2011 Table 36: Hepatitis B Therapeutics, Global, Overall Sponsors, 2011 Table 37: Hepatitis B Therapeutics, Global, Top 10 Companies by Phase, 2011 Table 38: Bristol-Myers Squibb Company - Pipeline, 2011 Table 39: Gilead Sciences - Pipeline, 2011 Table 40: GlaxoSmithKline Plc. - Pipeline, 2011 Table 41: Other Companies - Hepatitis B Therapeutics, 2011 Table 42: Hepatitis B Therapeutics, Global, Deals - 2011
List Of Figures Figure 1: Genotype of Hepatitis B Virus and its Geographical Distribution Figure 2: Hepatitis B - Prevalence of HBV Infection in the World by Country Figure 3: Hepatitis B - Areas and Features of Hepatitis B Prevalence Figure 4: Geographic Patterns of Hepatitis B Disease Burden Figure 5: Structure of Hepatitis B Virus
Website : http://www.aarkstore.com/
AArkstore enterprise Figure 6: Summary of Hepatitis B Virus Characteristics Figure 7: Hepatitis B - Interpretation of Hepatitis B Virus Serology Figure 8: Hepatitis B - Life Cycle of HBV Figure 9: Hepatitis B - Spectrum of Liver Disease After HBV Infection Figure 10: Hepatitis B - Childhood Vaccination Schedule Figure 11: Hepatitis B Therapeutics Market, Global, Revenue ($m), 2006 - 2011 Figure 12: Hepatitis B Therapeutics Market, Global, Forecast ($m), 2011 - 2019 Figure 13: Hepatitis B Therapeutics Market, The US, Revenue ($m), 2006 - 2011 Figure 14: Hepatitis B Therapeutics Market, The US, Forecast ($m), 2011 - 2019 Figure 15: Hepatitis B Therapeutics Market, France, Revenue ($m), 2006 - 2011 Figure 16: Hepatitis B Therapeutics Market, France, Forecast ($m), 2011 - 2019 Figure 17: Hepatitis B Therapeutics Market, Germany, Revenue ($m), 2006 - 2011 Figure 18: Hepatitis B Therapeutics Market, Germany, Forecast ($m), 2011 - 2019 Figure 19: Hepatitis B Therapeutics Market, Italy, Revenue ($m), 2006 - 2011 Figure 20: Hepatitis B Therapeutics Market, Italy, Forecast ($m), 2011 - 2019 Figure 21: Hepatitis B Therapeutics Market, Spain, Revenue ($m), 2006 - 2011 Figure 22: Hepatitis B Therapeutics Market, Spain, Forecast ($m), 2011 - 2019 Figure 23: Hepatitis B Therapeutics Market, The UK, Revenue ($m), 2006 - 2011 Figure 24: Hepatitis B Therapeutics Market, The UK, Forecast ($m), 2011 - 2019 Figure 25: Hepatitis B Therapeutics Market, Japan, Revenue ($m), 2006 - 2011 Figure 26: Hepatitis B Therapeutics Market, Japan, Forecast ($m), 2011 - 2019 Figure 27: Opportunity and Unmet Need in the Hepatitis B Therapeutics Market Figure 28: Strategic Competitor Assessment of the Marketed Products in Hepatitis B Therapeutics, 2011
Website : http://www.aarkstore.com/
AArkstore enterprise Figure 29: Hepatitis B Therapeutics Pipeline by Phase of Clinical Development, 2011 Figure 30: Hepatitis B Therapeutics Market, Global, Pipeline by Mechanism of Action (%), 2011 Figure 31: Technology Trends Analytics Framework, 2011 Figure 32: Hepatitis B Therapeutics, Global, Clinical Trials by Country, 2011 Figure 33: Hepatitis B Therapeutics, Global, Clinical Trials by Phase (%), 2011 Figure 34: Hepatitis B Therapeutics, Global, Clinical Trials by Status of Development (%), 2011 Figure 35: Hepatitis B Therapeutics, Global, Prominent Sponsors (%), 2011 Figure 36: Hepatitis B Therapeutics, Global, Overall Sponsors (%), 2011 Figure 37: Hepatitis B Therapeutics, Global, Top 10 Companies by Phase, 2011 Figure 38: Hepatitis B Therapeutics Market, Drivers and Restraints, 2011 Figure 39: Implications for Future Market Competition in the Hepatitis B Therapeutics Market, 2011 Figure 40: Hepatitis B Therapeutics Market, Clinical Pipeline by Company, 2011 Figure 41: GlobalData Market Forecasting Model
Discount Reports: Laryngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Melanoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Nasopharyngeal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Anal Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Bile Duct Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Leiomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019 WaldenstrÜm’s Macroglobulinemia Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Website : http://www.aarkstore.com/
AArkstore enterprise Chemotherapy-Induced Nausea and Vomiting (CINV) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
About Aarkstore Enterprise Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.
You can order full Report with TOC and Sample page visit: http://www.aarkstore.com/pharmaceuticals-healthcare/60345/hepatitis-btherapeutics-pipeline-assessment-and-market-forecasts
Contact Details: Aarkstore Enterprise Phone: +91 998 729 5242 Email: enquiry@aarkstore.com Our Website: http://www.aarkstore.com Facebook: https://www.facebook.com/aarkstoredotcom Linkedin: http://www.linkedin.com/company/aarkstore-enterprise
Website : http://www.aarkstore.com/